Increased expression of interleukin-1 receptor characterizes anti-estrogen-resistant ALDH(+) breast cancer stem cells
Sims, Andrew H
Hull, N J
Brown, M. E.
Brooks, M. D.
Wicha, M. S.
Howell, Sacha J
Clarke, Robert B
Simões, Bruno M
AffiliationManchester Breast Centre, Division of Cancer Sciences, University of Manchester, Manchester
MetadataShow full item record
AbstractEstrogen-receptor-positive breast tumors are treated with anti-estrogen (AE) therapies but frequently develop resistance. Cancer stem cells (CSCs) with high aldehyde dehydrogenase activity (ALDH+ cells) are enriched following AE treatment. Here, we show that the interleukin-1? (IL-1?) signaling pathway is activated in ALDH+ cells, and data from single cells reveals that AE treatment selects for IL-1 receptor (IL1R1)-expressing ALDH+ cells. Importantly, CSC activity is reduced by an IL1R1 inhibitor in AE-resistant models. Moreover, IL1R1 expression is increased in the tumors of patients treated with AE therapy and predicts treatment failure. Single-cell gene expression analysis revealed that at least two subpopulations exist within the ALDH+ population, one proliferative and one quiescent. Following AE therapy the quiescent population is expanded, which suggests CSC dormancy as an adaptive strategy that facilitates treatment resistance. Targeting of ALDH+IL1R1+ cells merits testing as a strategy to combat AE resistance in patients with residual disease. Keywords: ALDH(+) cells; IL1R1; anti-estrogens; breast cancer stem cells; dormancy.
CitationSarmiento-Castro A, Caamano-Gutierrez E, Sims AH, Hull NJ, James MI, Santiago-Gomez A, et al. Increased Expression of Interleukin-1 Receptor Characterizes Anti-estrogen-Resistant ALDH(+) Breast Cancer Stem Cells. Stem Cell Reports. 2020;15(2):307-16.
JournalStem Cell Reports
- The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance.
- Authors: Januchowski R, Wojtowicz K, Zabel M
- Issue date: 2013 Sep
- Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/β-catenin signaling.
- Authors: Debeb BG, Lacerda L, Xu W, Larson R, Solley T, Atkinson R, Sulman EP, Ueno NT, Krishnamurthy S, Reuben JM, Buchholz TA, Woodward WA
- Issue date: 2012 Nov
- High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability.
- Authors: Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, Allan AL
- Issue date: 2009 Aug
- High NRF2 level mediates cancer stem cell-like properties of aldehyde dehydrogenase (ALDH)-high ovarian cancer cells: inhibitory role of all-trans retinoic acid in ALDH/NRF2 signaling.
- Authors: Kim D, Choi BH, Ryoo IG, Kwak MK
- Issue date: 2018 Aug 30
- Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.
- Authors: Yang Z, Guo F, Albers AE, Sehouli J, Kaufmann AM
- Issue date: 2019 May